Search

Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its first quarter 2023 financial results today.

… Monday, May 15, 2023 Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its first quarter 2023 financial results today: MSK’s financial performance in the first quarter of 2023 instills confidence that by following the sound financial strategy we have put in place we

These special awards are presented to researchers and global oncology leaders who have reshaped cancer care around the world and are among the highest honors bestowed by ASCO.

… Tuesday, March 29, 2022 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Fumiko Chino, MD; Craig B. Thompson, MD; and Jedd D. Wolchok, MD, PhD, FASCO, have been honored by the American Society of Clinical Oncology (ASCO) and Conquer Cancer, the ASCO Foundation, with three prestigious

CyberKnife is a brand name for one of several available stereotactic radiosurgery devices that deliver radiation with linear accelerators. MSK uses a similar device, made by a company called Varian, that destroys tumors with extremely precise, very intense doses of radiation.

… Monday, February 24, 2014 Summary CyberKnife is a brand name. It refers to a stereotactic body radiation therapy device that delivers radiation using advanced imaging technology. MSK uses similar technology as part of an approach called MSK Precise TM . This method destroys tumors with very intense doses

Discover how a watch-and-wait approach to treating rectal cancer can help people avoid surgery and preserve normal body functions.

… Tuesday, January 15, 2019 Summary The biggest study of its kind in North America finds a watch-and-wait strategy can have excellent long-term results for some people with rectal cancer. Cancers of the colon and rectum are often grouped together as colorectal cancer because both are part of the large

With the help of machine learning, computational biologists are learning to predict how cancers will evolve.

… Wednesday, June 23, 2021 From amoebas to zebras, all living things evolve. They change over time as pressures from the environment cause individuals with certain traits to become more common in a population while those with other traits become less common. Cancer is no different. Within a growing tumor

Learn about gastrointestinal distress, one of the more common side effects of immunotherapy.

… Thursday, January 31, 2019 Summary One of the most common immunotherapy side effects is gastrointestinal distress. MSK gastroenterologist David Faleck explains why this happens and how to find relief. Chances are that you have heard some buzz about immunotherapy . This type of cancer treatment trains

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024 Breakthrough Prize in Life Sciences.

… Thursday, September 14, 2023 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024  Breakthrough Prize in Life Sciences

Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

… Saturday, June 4, 2011 Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer , according to a new study. Results from the phase III “OCEANS” trial were presented today by the lead author, Carol Aghajanian, MD , of Memorial Sloan

The FDA has approved an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. The clinical trials resulting in the drug’s approval were led by Dr. Sandra D’Angelo of MSK.

… Friday, August 2, 2024 The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleucel (Tecelra ® , also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called  synovial sarcoma . Afami-cel is the first engineered

A new imaging approach could shorten the time needed to determine whether a brain tumor treatment is working.

… Friday, July 13, 2018 Summary It is hard to monitor whether treatment for a brain tumor is having an effect. A new diagnostic technique called hyperpolarized MRI provides a clear image of the brain’s metabolic activity. This can give important clues about whether a treatment is working in a shorter time